Back to articles

Investigational Nonstimulant Agent Showing Promise for ADHD


If results from a just-published study are vetted during FDA review of atomoxetine (Lilly), U.S. clinicians should have available a nonstimulant medication for treatment of attention-deficit/hyperactivity disorder (ADHD) by the latter half of 2002. A highly specific norepinephrine reuptake inhibitor, atomoxetine has been tested in clinical trials in children, adolescents, and adults, and Lilly recently filed an NDA seeking approval for treatment of ADHD in all three age groups.


Michelson D et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.